Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Shangeng Weng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8802-6616; OpenAlex author ID A5080152110. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 6 papers

Papers 19

  1. Corrigendum to "High glucose-induced mitochondrial fission drives pancreatic cancer progression through the H3K18la/TTK/BUB1B signal pathway" [Cell Signal, 135… Last author DOI 10.1016/j.cellsig.2025.112087↗
  2. Corrigendum to "High glucose-induced mitochondrial fission drives pancreatic cancer progression through the H3K18la/TTK/BUB1B signal pathway" [Cellular Signall… Last author DOI 10.1016/j.cellsig.2026.112467↗
  3. Integrative Transcriptomic and Proteomic Profiling Defines Secretory and Immune Related Subtypes in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1021/acs.jproteome.5c01146↗
  4. Prostaglandin E2-driven dedifferentiation of Schwann cells leads to perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41392-026-02648-x↗
  5. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Last author DOI 10.1038/s41419-025-08135-5↗
  6. PIEZO1 enhances pancreatic cancer neurotropism. Co-author DOI 10.1186/s12935-026-04244-z↗
  7. The CD39-CD73-adenosine axis: Master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.bbcan.2025.189443↗
  8. High glucose-induced mitochondrial fission drives pancreatic cancer progression through the H3K18la/TTK/BUB1B signal pathway. Last author DOI 10.1016/j.cellsig.2025.112027↗
  9. Intratumoral microbiota-driven macrophage reprogramming in pancreatic cancer via Blautia metabolite 6-hydroxyhexanoic acid. Last author DOI 10.1016/j.intimp.2025.115421↗
  10. Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinoma. Last author DOI 10.1016/j.tranon.2025.102532↗
  11. Abnormal levels of miRNA in pancreatic cancer are linked to tumor progression by regulating the translation of tumor-associated mRNA. Last author DOI 10.1080/07853890.2025.2541315↗
  12. Contrast-enhanced CT radiomics combined with multiple machine learning algorithms for preoperative identification of lymph node metastasis in pancreatic ductal… Last author DOI 10.3389/fonc.2024.1342317↗
  13. Comparison of multiple machine learning models for predicting prognosis of pancreatic ductal adenocarcinoma based on contrast-enhanced CT radiomics and clinica… Co-author DOI 10.3389/fonc.2024.1419297↗
  14. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Last author DOI 10.1038/s41419-023-05715-1↗
  15. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Last author DOI 10.1038/s41419-023-05939-1↗
  16. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Co-author DOI 10.1186/s13062-022-00347-5↗
  17. N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer. Co-author DOI 10.1186/s13578-022-00844-0↗
  18. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by competitively sponging miR-139-5p and activating the W… Last author DOI 10.21203/rs.3.rs-1242747/v1↗
  19. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Last author DOI 10.3389/fonc.2022.962204↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yun Zhong · 6 shared papers, 2022–2026 · strength 1.51
  2. Fadian Ding · 5 shared papers, 2025–2026 · strength 1.35
  3. Shihui Lai · 6 shared papers, 2022–2026 · strength 1.21
  4. Chengjie Lin · 6 shared papers, 2022–2026 · strength 1.20
  5. Xiang Zhang · 6 shared papers, 2022–2023 · strength 1.06
  6. Yue Huang · 5 shared papers, 2022–2024 · strength 1.00
  7. Zhenyun Guo · 4 shared papers, 2022–2026 · strength 0.87
  8. Yan Wang · 4 shared papers, 2022–2023 · strength 0.70
  9. Ling Wang · 2 shared papers, 2026 · strength 0.59
  10. Feng Gao · 2 shared papers, 2026 · strength 0.59
  11. Qicai Liu · 2 shared papers, 2026 · strength 0.59
  12. Qiang Huang · 2 shared papers, 2025–2026 · strength 0.53
  13. Liang Wang · 3 shared papers, 2022 · strength 0.51
  14. Guozhong Liu · 2 shared papers, 2024 · strength 0.45
  15. Shizhao Lin · 1 shared paper, 2026 · strength 0.32
  16. Jinhong Li · 1 shared paper, 2026 · strength 0.32
  17. Tianhong Teng · 1 shared paper, 2026 · strength 0.32
  18. Xiaolong Liu · 1 shared paper, 2025 · strength 0.30
  19. Qiangda Chen · 1 shared paper, 2025 · strength 0.30
  20. Haitao Zhang · 1 shared paper, 2026 · strength 0.29
  21. Qiyu Chi · 1 shared paper, 2025 · strength 0.28
  22. Yu Pan · 1 shared paper, 2025 · strength 0.28
  23. Jiahong Dong · 1 shared paper, 2026 · strength 0.27
  24. Qiang Huang · 1 shared paper, 2025 · strength 0.26
  25. Chengjie Lin · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.